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SUMMARY
Dopaminergic neurons in the ventral tegmental area (VTA) are well known for their role in 
mediating the positive reinforcing effects of drugs of abuse. Here, we identify in rodents and 
humans a population of VTA dopamine neurons co-expressing corticotropin releasing factor 
(CRF). We provide further evidence in rodents that chronic nicotine exposure upregulates CRF 
mRNA in dopaminergic neurons of the posterior VTA, activates local CRF1 receptors, and blocks 
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nicotine-induced activation of transient GABAergic input to dopaminergic neurons. Local 
downregulation of CRF mRNA and specific pharmacological blockade of CRF1 receptors in the 
VTA reversed the effect of nicotine on GABAergic input to dopaminergic neurons, prevented the 
aversive effects of nicotine withdrawal, and limited the escalation of nicotine intake. These results 
link the brain reward and stress systems within the same brain region in signaling the negative 
motivational effects of nicotine withdrawal.
INTRODUCTION
Drug addiction has been hypothesized to be driven by two mechanisms; reduction of the 
activity of the brain reward system1 and enhanced function of the anti-reward brain stress 
system2, concepts known as within- and between-system neuroadaptations, respectively3. 
Prominent downregulation of the mesolimbic dopamine (DA) reward system originating in 
the ventral tegmental area (VTA) and upregulation of the corticotropin-releasing factor 
(CRF) brain stress system originating in the extended amygdala have been observed in 
rodents, nonhuman primates, and humans during abstinence from drugs of abuse, including 
tobacco4,5.
The VTA is a critical region for nicotine dependence6, and several groups have examined 
the mechanisms behind DA and CRF neuroadaptations7–13. However, most of these studies 
were performed in nondependent animals, and these studies postulated that VTA CRF is 
released from axons that originate in the forebrain and not from local CRF neurons7–13. 
Thus, how the VTA DA and CRF systems interact in nicotine dependence and withdrawal is 
essentially unknown.
Here, we identify in rodents and humans a novel population of CRF neurons in the VTA and 
demonstrate that recruitment of these CRF neurons in the VTA after chronic nicotine 
contributes to a within-system neuroadaptation of DA neurons to mediate the negative 
motivational state elicited by nicotine withdrawal.
RESULTS
Nicotine dependence upregulates CRF mRNA in the pVTA
To test whether nicotine dependence upregulates CRF in the brain stress and reward 
systems, we first measured CRF mRNA in two key regions of the CRF brain stress system, 
the paraventricular nucleus of the hypothalamus (PVN) and central nucleus of the amygdala 
(CeA), as well as in the VTA, using quantitative real-time polymerase chain reaction (RT-
PCR). Groups of mice were made nicotine-dependent by chronic exposure to nicotine 
delivered by osmotic minipumps (7 mg/kg/d)14,15. Brain punches of the PVN, CeA, and 
VTA (Fig. 1a) were sampled in saline-treated mice, dependent mice with nicotine 
minipumps, or 8 h after removal of the minipump (withdrawn mice)14. We consistently 
detected low levels of CRF mRNA in the VTA in saline-treated mice. CRF mRNA levels 
were 7–15 times lower in the VTA than in the CeA and PVN (F2,33=4.9, p=0.014, Fig. S1), 
in accordance with the fact that the CeA and PVN contain large populations of cell bodies 
that express CRF mRNA, whereas similar neurons have not been reported in the VTA16 
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until now. Chronic exposure to nicotine increased CRF mRNA levels in the VTA in both the 
dependent and withdrawn groups of mice (F2,100 = 2.7, p = 0.034), without altering CRF 
expression in the PVN or CeA (Fig. 1b). Considering that CRF neurons in the CeA and PVN 
project to and synapse with both DA and γ-aminobutyric acid (GABA) neurons in the 
VTA17, and that CRF release in the VTA is potentiated after repeated but not acute cocaine 
exposure8, the increase in CRF mRNA in the VTA observed herein could originate from 
either axonal transport of CRF mRNA to the VTA or the synthesis of CRF mRNA in local 
VTA neurons.
Identification of a novel population of CRF neurons in the pVTA
To test the hypothesis that CRF mRNA is synthesized locally in the VTA, we performed in 
situ hybridization (ISH) for CRF mRNA in a separate cohort of mice that were drug-naive or 
treated with acute nicotine (1.5 mg/kg), chronic nicotine (7 mg/kg/day for 12 days), or 
chronic nicotine and withdrawal (8 h). A significant population of CRF neurons with dense 
CRF mRNA in cell bodies could be detected bilaterally in the VTA in all groups, with the 
majority of neurons localized in the posterior VTA (pVTA), dorsal to the interpeduncular 
nucleus (IPN) (Fig. 2). No significant difference in the number of neurons was observed 
between groups (F24,180=0.82, p=0.71, Fig. S2), demonstrating that the increase in CRF 
mRNA was attributable to an increase in the production of CRF within neurons and not to 
an increase in the number of CRF neurons. To confirm the specificity of the CRF mRNA 
ISH, we performed urocortin mRNA ISH on adjacent sections. Urocortin is a structurally 
related peptide of the CRF family with significant affinity for the CRF2 receptor18. No 
urocortin-positive neurons were observed in the VTA (Fig. S3), whereas numerous 
urocortin-positive neurons were observed in the Edinger-Westphal nucleus (Fig. S3), an area 
that is known to contain a large population of urocortin neurons18. Complementary to these 
results, a recent study demonstrated that nicotine selectively activates dopaminergic neurons 
in the pVTA but not anterior VTA (aVTA), suggesting that CRF-expressing neurons in the 
pVTA may be dopaminergic19. To test this hypothesis, we then examined co-expression of 
CRF in VTA DA neurons in both mice and humans.
CRF mRNA is expressed in DA neurons
We performed double labeling of CRF mRNA and DA neurons using CRF mRNA 
radioactive (Fig. 3a), and fluorescent ISH coupled with tyrosine hydroxylase (TH) 
immunohistochemistry (Fig. 3c, d) in mice. CRF mRNA-positive neurons were located 
bilaterally in the VTA in TH-enriched regions (Fig. 3b), and 95.2 ± 4.8% of them co-
expressed TH (Fig. 3c, d). To further confirm the existence of VTA CRF/DA neurons and 
test their relevance to humans, we performed CRF chromogenic ISH coupled with TH 
immunohistochemistry in VTA samples from three non-smoker humans without any 
psychiatric disorders (see Supplementary Table 1 for details). Of 600 CRF neurons, we 
found that 97.8 ± 0.7% of CRF neurons were colocalized with DA neurons (Fig. 4), 
confirming the existence of VTA CRF/DA neurons in both rodents and humans.
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Withdrawal-induced CRF peptide depletion in the pVTA and IPN
Increased CRF release during drug withdrawal is associated with decreased immunodensity 
of CRF peptide in neuropils. The decrease in CRF immunodensity reflects CRF depletion 
from synaptic vesicles subsequent to a local increase in CRF release20,21. Thus, we used 
CRF immunohistochemistry to examine whether the recruitment of CRF neurons in the 
pVTA is also associated with a local decrease in CRF peptide density in neuropils during 
withdrawal from chronic nicotine. Densitometry analysis revealed that both nicotine 
dependence and withdrawal from chronic nicotine decreased CRF peptide density compared 
with saline-treated mice in the pVTA (F2,31 = 4.40, p = 0.02; Fig. S4a), interpeduncular 
nucleus (IPN; F2,49 = 4.24, p = 0.020; Fig S4d), and CeA (F2,67 = 3.15, p = 0.049; Fig. S4c) 
but not aVTA (F2,23 = 0.03, p = 0.97; Fig. S4a) or PVN (F2,21 = 0.75, p = 0.48; Fig. S4b), 
demonstrating the specificity of these effects. The combined observations that chronic 
nicotine exposure increases CRF mRNA expression and decreases CRF peptide density in 
the pVTA and IPN suggest that CRF/DA neurons in the pVTA may release CRF locally in 
the pVTA and IPN during nicotine dependence. However, the possibility that CRF may also 
be released from extrinsic projection neurons, such as CRF neurons in the CeA, cannot be 
ruled out because decreased immunodensity was also observed in the CeA (Fig. S4c). The 
decreased CRF immunodensity in the CeA replicates results obtained with alcohol-
dependent rats21 and extends this work to nicotine-dependent and -withdrawn mice.
pVTA CRF mRNA downregulation prevents nicotine dependence-induced dysregulation of 
GABA-DA synapses
The downregulation of VTA DA neuron activity is a key feature of addiction, and recent 
results have shown that nicotine-induced GABA currents are critical for the phasic 
activation of dopamine neurons22. To test whether CRF mRNA-expressing neurons in the 
pVTA play a role in the synaptic control of DA neurons, we tested the causal relationship 
between downregulation of CRF mRNA in the pVTA of nicotine-dependent and -withdrawn 
mice and the effect of nicotine on GABAergic currents in DA neurons. Local 
downregulation of CRF mRNA was performed using an adeno-associated viral vector that 
encodes a short-hairpin RNA targeting CRF mRNA (AAV2-shCRF) or a non-targeting 
sequence (AAV2-shSCR; Fig. S5a, b). The AAV2-shCRF vector decreased the amount of 
CRF mRNA by 88.0 ± 6.2% as measured by RT-PCR on VTA punches (t10 = 11.12, p = 
0.0001, n = 6 mice/condition). Some neurons exhibited an even stronger downregulation, 
having no detectable CRF mRNA remaining after treatment with the silencing vector, such 
that the total number of CRF-positive neurons decreased by 26% (Fig. S5c, d).
Whole-cell voltage-clamp recordings of pharmacologically isolated GABAA receptor-
mediated spontaneous inhibitory postsynaptic currents (sIPSCs) were first performed in 
putative pVTA DA neurons from naive mice. Dopamine neurons were identified at the time 
of recording by previously published functional criteria23,24 (Fig. S6), and a subset of 
neurons was collected after recording for TH expression using single-cell RT-PCR. To 
examine the effects of nicotine dependence on changes in GABAergic transmission in 
pVTA DA neurons with and without downregulation of CRF mRNA, neurons infected with 
either AAV2-shSCR or AAV2-shCRF were identified during withdrawal (6–8h) by the 
presence of green fluorescent protein (GFP) in the cell body (Fig. 5c). In naive mice, acute 
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application of nicotine (1 μM) onto pVTA DA neurons produced a transient, significant 
increase in sIPSC frequency from 1.2 ± 0.2 Hz to 1.9 ± 0.3 Hz (t7 = 5.048, p = 0.0015, 
paired t-test; Fig. 5a, b; 172.9 ± 18.5% of control, t7 = 3.93, p = 0.0057, one-sample t-test; 
Fig. 5f), consistent with previous reports25,26. Nicotine also increased sIPSC frequency in 
pVTA DA neurons from mice implanted with saline minipumps and infected with AAV2-
shSCR or AAV2-shCRF (176.9 ± 18.2% of control; t11 = 4.217, p = 0.0014 and 171.5 ± 
16.7% of control; t11 = 4.248, p = 0.0013, respectively; Fig 5f). In contrast, in pVTA DA 
neurons from nicotine-dependent mice injected with AAV2-shSCR, acute application of 
nicotine (1 μM) produced no change in sIPSC frequency (97.7 ± 1.8% of control; t10 = 
1.228, p = 0.2474; Fig. 5d, f), which was significantly different from the effects observed in 
naïve mice or mice implanted with saline minipumps (one-way ANOVA, F4,48= 4.704, p = 
0.0028). However, during acute application of nicotine (1 μM) in pVTA DA neurons from 
nicotine-dependent mice injected with AAV2-shCRF, the nicotine-induced increase in 
sIPSC frequency was restored (171.2 ± 17.3 % of control; t9 = 4.108, p = 0.0026, one-
sample t-test; Fig. 5e, f), which was significantly different from that observed in pVTA DA 
neurons from nicotine-dependent mice injected with AAV2-shSCR (unpaired t-test; t19 = 
4.426, p = 0.0003), but not different from that observed in naive mice. To confirm the 
identity of the putative DA neurons, we performed single-cell RT-PCR after recordings to 
detect the presence of TH. The majority (13/18, 72%) of the VTA cells examined by single-
cell PCR were TH-positive, and the electrophysiological results were similar when only TH-
positive neurons were included (Fig. S7). Collectively, these data demonstrate that nicotine-
induced activation of GABA neurons, a key mechanism required for DA neuron firing22, is 
deficient in nicotine-dependent mice, and that downregulation of CRF mRNA in the VTA 
can reverse the effect of nicotine dependence.
pVTA CRF mRNA downregulation prevents the aversive effects of nicotine withdrawal
To test whether CRF mRNA-expressing neurons in the pVTA play a role in the motivational 
effects of nicotine dependence, we examined the causal relationship between 
downregulation of CRF mRNA in the pVTA of nicotine-dependent and -withdrawn mice 
and the expression of conditioned place aversion to nicotine withdrawal and anxiety-like 
behavior (Fig. 6a). In the place conditioning paradigm, a two-way ANOVA revealed a 
significant interaction between AAV2 injection and nicotine history (F1,40 = 5.80, p = 0.021; 
Fig. 6b). Nicotine-dependent and -withdrawn mice infused with the AAV2-shSCR control 
vector in the pVTA showed an aversive motivational response to the withdrawal-paired 
environment (p = 0.032), which was not observed in mice infused with the AAV2-shCRF 
vector (p = 0.6392). Mice that were injected with the AAV2-shCRF vector outside the 
pVTA (mostly located dorsal (red nucleus) and lateral (substantia nigra) to the pVTA) 
showed an aversive response to nicotine withdrawal similar to control mice (unpaired t-test 
t16 = 0.0255, p = 0.798; Fig S8), demonstrating the anatomical specificity of this effect. 
Furthermore, nondependent mice given either the AAV2-shSCR or AAV2-shCRF vector in 
the pVTA and an acute aversive injection of nicotine (1.75 mg/kg)14,15 showed an aversive 
response to the nicotine-paired environment (Fig. 6b), demonstrating that the lack of 
aversion to withdrawal in dependent mice infused with the silencing vector was not 
attributable to a general impairment of conditioned place aversion, but was specific to 
nicotine withdrawal in dependent mice. Altogether, these results suggest that CRF mRNA in 
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the pVTA does not mediate a general aversive response to acute nicotine but specifically 
mediates aversion to nicotine withdrawal in dependent subjects. These results establish a 
causal relationship between the recruitment of CRF mRNA-expressing neurons in the pVTA 
during withdrawal from chronic nicotine and the aversive motivational response to nicotine 
withdrawal.
Activation of the brain CRF-CRF1 receptor system is associated with increased anxiety-like 
behavior in humans and animals and is hypothesized to be responsible for the negative 
emotional state after protracted abstinence27. To test this hypothesis, we measured open 
field activity to evaluate anxiety-like behavior during protracted abstinence (3–4 weeks). 
Mice injected with the AAV2-shSCR vector spent significantly less time in the central area 
of the open field than mice injected with the AAV2-shCRF vector (unpaired t-test t14 = 2.84, 
p = 0.013; Fig. 6c), an effect that was not attributable to a decrease in locomotion (AAV2-
shSCR: 2181 ± 215 cm; AAV2-shCRF: 2307 ± 146 cm; t14 = 0.49, p = 0.64). These results 
demonstrate that upregulation of CRF mRNA in the pVTA is required for the anxiogenic-
like effects of protracted nicotine abstinence.
pVTA CRF mRNA downregulation decreases abstinence-induced escalation of nicotine 
intake
To test whether CRF mRNA-expressing neurons in the pVTA play a role in the motivation 
to take nicotine during abstinence, we infused the same AAV2-shCRF/shSCR vectors in the 
pVTA of rats, and measured nicotine self-administration 4 weeks later. In rats given short 
access (1 h/day) to nicotine self-administration for 10 days, downregulation of CRF mRNA 
in the VTA did not affect nicotine intake (unpaired t-test; t17 = 0.59, p = 0.28; Fig. 7). We 
then gave the rats long access (21 h/day) to nicotine self-administration and measured 
nicotine intake after 7 days of long access and after 48 h of abstinence27–29. Infusion of 
AAV2-shCRF decreased nicotine intake in long access rats (unpaired t-test t14 = 2.32, p = 
0.018), and prevented abstinence-induced increases in nicotine intake, whereas the rats that 
received AAV2-shSCR showed a significant increase in nicotine intake after 48 h of 
abstinence (F1,14 = 4.91, p = 0.044; Fig. 7). These results demonstrate that pVTA CRF 
mRNA downregulation decreases excessive nicotine intake and is particularly effective at 
decreasing the abstinence-induced escalation of nicotine intake.
Blocking CRF1 receptors prevents the aversive effect of nicotine withdrawal
The present results revealed a depletion of CRF peptide in the pVTA during nicotine 
withdrawal, hypothesized to reflect a local increase in CRF release20,21. To further test this 
hypothesis, we examined whether the activation of CRF1 receptors in the pVTA is necessary 
for the conditioned aversive motivational response to a withdrawal-paired environment 
shown by nicotine-dependent and -withdrawn mice14,15. We administered the CRF1 receptor 
antagonist N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-di-methyl-
pyrazolo[1,5-a]pyrimidin-7-amine (MPZP; 20 mg/kg, s.c.)27 prior to place conditioning in 
nondependent mice given acute nicotine, nicotine-dependent mice with minipumps (7 
mg/kg/day), or mice in spontaneous withdrawal (8 h) from chronic nicotine (Fig. 8a). A two-
way ANOVA showed a significant effect of systemic MPZP treatment (F3,103 = 20.51, p < 
0.0001; Fig 8b). Withdrawn mice pretreated with vehicle showed a conditioned place 
Grieder et al. Page 6
Nat Neurosci. Author manuscript; available in PMC 2015 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
aversion to a withdrawal-paired environment that was blocked by MPZP (p = 0.0043), 
demonstrating that activation of CRF1 receptors during withdrawal is required for the 
aversive motivational response to nicotine withdrawal. Nicotine-dependent mice that were 
not in withdrawal and pretreated with saline showed a conditioned place preference for the 
nicotine-paired environment that was not blocked by MPZP pretreatment (p = 0.9085). 
These results suggest that the activation of CRF1 receptors is not required for the rewarding 
motivational response to chronic nicotine in dependent mice. To further evaluate the 
specificity of this effect, we tested the effect of CRF1 receptor antagonism on the 
conditioned avoidance response to an acute aversive dose of nicotine14. Nondependent mice 
given acute nicotine and pretreated with saline showed a conditioned place aversion to the 
nicotine-paired environment that was not blocked by MPZP pretreatment (p = 0.9228) 
similar to the results obtained using viral vector-mediated CRF mRNA silencing. Mice 
treated with chronic saline and pretreated with vehicle or MPZP showed no motivational 
response to a novel environment or to MPZP (p = 0.8697), confirming the specificity of 
these results. These results demonstrate that activation of CRF1 receptors is selectively 
required to mediate the aversive motivational response to nicotine withdrawal in dependent 
mice but not the aversive (in nondependent mice) or rewarding (in dependent mice) 
motivational effects of nicotine.
To test whether activation of CRF1 receptors specifically in the pVTA mediates the 
conditioned aversive motivational response to nicotine withdrawal, we measured place 
conditioning in separate groups of mice after infusion, prior to conditioning, of MPZP (0.14 
ng/0.3 μl) or vehicle in the aVTA (Fig. 8c) and pVTA (Fig. 8d). A two-way ANOVA 
revealed a significant interaction between treatment and nicotine history (F3,76 = 3.351, p = 
0.0233; Fig. 8e). Nicotine-dependent mice that were in withdrawal and pretreated with 
vehicle showed an aversive response to the withdrawal-paired environment that was blocked 
in withdrawn mice pretreated with intra-pVTA MPZP (p = 0.0063). However, the ability of 
MPZP to block nicotine withdrawal aversions was not observed when the CRF antagonist 
was infused into the aVTA (p = 0.7108). These results demonstrate that CRF1 receptor 
activation, specifically in the pVTA, is necessary for the acquisition of the aversive 
motivational response to nicotine withdrawal in dependent mice. Similar to mice that 
received systemic MPZP or the AAV2-shCRF, mice in a nondependent motivational state 
that received intra-pVTA MPZP or vehicle prior to acute nicotine administration showed a 
conditioned avoidance to the acute nicotine-paired environment (p = 0.7323). Intra-VTA 
MPZP had no motivational effects on its own, such that mice implanted with saline 
minipumps showed neither a preference nor aversion to a MPZP-paired environment (p = 
0.8996).
DISCUSSION
This report identifies a novel population of DA neurons in the VTA that co-express CRF in 
both rodents and humans. Chronic exposure to nicotine increased the levels of CRF mRNA 
in the pVTA associated with a depletion of CRF peptide in VTA and IPN neuropils and 
blocked nicotine-induced activation of GABAergic input onto DA neurons. Downregulation 
of CRF mRNA in the pVTA restored GABAergic control over DA neurons and prevented 
the motivational effects of nicotine withdrawal as measured by conditioned place aversion, 
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anxiety-like behavior, and escalated nicotine self-administration. Pharmacological testing 
further demonstrated that the motivational effects of nicotine withdrawal were mediated by 
activation of CRF1 receptors in the pVTA.
The detection of CRF neurons in the brain can be very challenging. To confirm the existence 
of this novel population of CRF neurons in the VTA, we utilized a variety of complementary 
approaches: RT-PCR, radioactive and chromogenic ISH, immunohistochemistry, and 
fluorescent ISH combined with immunohistochemistry. These techniques revealed direct 
evidence of CRF neurons in the VTA in rodents and humans. To further confirm the 
existence of CRF neurons in the VTA, we used several controls, including RT-PCR of 
housekeeping genes, CRF immunodensity in the aVTA, and ISH of urocortin, a member of 
the CRF family that is structurally related to CRF. Confirming the specificity of the present 
results, housekeeping genes were not upregulated, CRF immunodensity was altered in the 
pVTA and IPN but not aVTA, and urocortin-positive neurons were not observed in the 
pVTA.
TH immunohistochemistry combined with CRF ISH clearly showed that the majority of 
CRF-positive neurons (95% in mice and 98% in humans) were colocalized with TH, a 
marker of DA neurons. CRF neurons were distributed bilaterally in the VTA, with the 
highest number observed in the pVTA in the region dorsal to the IPN. This increase in CRF 
mRNA was associated with the depletion of CRF in IPN and pVTA neuropils (but not 
aVTA), suggesting that the increase in CRF mRNA in the VTA was associated with 
increased CRF release in the pVTA and IPN. Virally-mediated CRF mRNA downregulation 
and pharmacological blockade of CRF1 receptors in the pVTA confirmed the physiological 
role of increased VTA CRF mRNA, CRF release, and CRF1 receptor activation in nicotine-
dependent mice.
These results suggest that VTA CRF neurons may release CRF through axons in the IPN, 
and both axons and dendrites in the pVTA to act as autocrine and paracrine-like signals30. 
Indeed, unlike classic neurotransmitters, neuropeptides are not only found in axons but are 
also found abundantly in dendrites31. CRF specifically is found in dendrites associated with 
endomembranes and large dense-core vesicles32, and CRF immunoreactivity has been 
observed both in axon terminals and dendrites in the VTA17. Many groups have attempted 
to measure CRF in the VTA in rats but failed because of the low concentration, high 
degradation rate, and low stability and recovery of CRF using microdialysis. The only report 
of CRF microdialysis in the VTA has not been replicated, and involved intense footshock 
stress33. New techniques are being developed based on cell-based neurotransmitter 
fluorescent engineered reporters to reliably measure physiological CRF levels, but these 
methods are still in their initial stages of development.
The decreased CRF immunodensity in the CeA is in accordance with previous reports 
showing increased CRF release27 and reduction of negative emotional states after blockade 
of CRF1 receptors in the CeA34. The lack of increased CRF mRNA in the CeA suggests that 
the VTA and CeA CRF neurons may be upregulated at different time points. Recent reports 
showing increased CRF mRNA in the CeA 16–24 h into withdrawal35,36 may explain why 
an increase was not observed 8 h into withdrawal in the present study. Taken together, these 
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studies demonstrate that blocking the CRF-CRF1 system in the CeA or VTA is sufficient to 
prevent the negative emotional states of nicotine withdrawal.
In addition to the upregulation of CRF mRNA in VTA DA neurons, chronic nicotine 
dysregulated GABA-DA synapses, demonstrated by the loss of inhibitory responses 
(sIPSCs) to acute nicotine in VTA DA neurons in dependent mice. Viral-mediated 
downregulation of CRF mRNA in the pVTA abolished the effect of chronic nicotine on 
GABA-DA synapses and prevented the motivational effect of withdrawal as measured by 
conditioned place aversion, anxiety-like behavior, and escalated nicotine self-administration 
after abstinence. These findings may explain why nicotine dependence produces in vivo 
decreases in tonic dopaminergic activity in the VTA15 and DA release in the nucleus 
accumbens37, whereas acute CRF1 receptor antagonism increases tonic DA activity38. These 
findings also may provide a mechanism for observed decreases in accumbal DA release in 
response to rewards after CRF administration in the VTA9, the decreased phasic dopamine 
release observed in cocaine-dependent rats39, and the decreased prefrontal dopamine 
metabolism after intra-VTA CRF administration40. Indeed, while pharmacological and 
optogenetic activation of VTA GABA neurons produces robust inhibition of DA 
neurons41,42, transient physiological activation of GABAergic input on DA neurons is 
required for DA firing22 because transient GABAergic inputs promote rebound firing in DA 
neurons. Altogether, these results demonstrate that the activation of a CRF-CRF1 system in 
the pVTA may dysregulate transient GABAergic inputs that are critical for dopaminergic 
firing. Similar effects of CRF on GABAergic input have been observed in the CeA43.
Increasing evidence suggests that a neurobiological switch occurs in the VTA during the 
transition from nondependent to drug-dependent motivational states15,44–46, suggesting that 
the effect of CRF1 receptor activation in dependent vs. non-dependent animals may be 
opposite. Our results showed a specific role for CRF in the pVTA in mediating the aversive 
response to nicotine withdrawal in dependent mice, but not to acute nicotine in 
nondependent mice. The specific effect on nicotine intake in LgA but not ShA rats is 
consistent with this hypothesis, demonstrating that the recruitment of VTA CRF/DA 
neurons significantly contributes to the development of nicotine dependence. The present 
results do not exclude the possibility that the expression of CRF in DA neurons alters 
plasticity in non-DA neurons and circuits in the VTA that may also alter DA function and 
have motivational significance46,47. However, taken with previous results demonstrating 
that nicotine withdrawal is signaled by a specific pattern of tonic VTA dopaminergic 
activity15, and activation of CRF1 receptors can mediate changes in VTA DA population 
activity38, the present results suggest that chronic nicotine leads to an upregulation of CRF 
in pVTA DA neurons that is released onto VTA CRF1 receptors to mediate the aversive 
motivational effects of nicotine withdrawal. Future studies are necessary to directly test this 
hypothesis for nicotine and other drugs of abuse.
The transition to drug dependence and drug addiction has been hypothesized to be driven 
and maintained by two relatively independent systems: downregulation of DA function in 
the VTA, a within-system neuroadaptation that leads to a reward deficit disorder48, and 
upregulation of CRF function, a between-system neuroadaptation that leads to a stress 
surfeit disorder49. Here, we identify a novel population of CRF neurons in the core of the 
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brain incentive salience/reward system, in DA neurons of the pVTA, and show that the 
upregulation of CRF mRNA and activation of CRF1 receptors locally in the pVTA occur 
after the induction of nicotine dependence and are required for the aversive motivational 
effects of nicotine withdrawal. This within-system neuroadaptation links the brain reward 
and stress systems within the same neurobiological substrate, providing evidence that DA 
and CRF interact within the VTA to mediate the aversive motivational effects of nicotine 
withdrawal in dependent subjects.
ONLINE METHODS
Animals
All animal use procedures were approved by the University of Toronto Animal Care 
Committee in accordance with the Canadian Council on Animal Care guidelines and The 
Scripps Research Institute Institutional Animal Care and Use Committee and were in 
accordance with National Institutes of Health guidelines. Adult male C57BL/6 mice (2–4 
months) (Charles River, Montreal, Canada, or Hollister, CA, USA) were housed in a 
temperature-controlled room with lights on from 7:00 AM to 7:00 PM. Adult male Wistar 
rats (2–4 months) (Charles River, Hollister, CA, USA) were housed in a temperature-
controlled room with lights on from 8:00 PM to 8:00 AM. Animals were grouped 2–4 per 
cages. Behavioral testing was performed during the dark cycle.
Drugs
Nicotine hydrogen tartrate salt (Sigma-Aldrich, Ontario, Canada) was dissolved in saline, 
pH 7.0 ± 0.4, and administered via osmotic minipumps (chronic nicotine, 7 mg/kg/day, 
minipump model 1002, Alzet, Cupertino, CA, USA) or subcutaneous injection (acute 
nicotine, 1.75 mg/kg). Nicotine-dependent and -withdrawn mice had their minipumps 
removed 8 h prior to experimentation at a time that corresponded to peak motivational 
withdrawal14. The CRF1 receptor antagonist MPZP was synthesized at The Scripps 
Research Institute (Richardson et al., 2008), dissolved in (2-hydroxypropyl)-beta-
cyclodextrin (HBC), and administered subcutaneously 20 min prior to conditioning or at a 
concentration of 0.14 μg/0.3 μl over 10 min for intra-VTA infusions.
Viral vector production
shRNA-encoding AAV2 vectors that target the CRF transcript were generated using the 
same procedure as described by Darcq et al. (2011). A shRNA sequence (shCRF, sense 
strand 5′-GGATCTCACCTTCCACCTTCT-3′) predicted to have high silencing efficiency 
was selected using Block-iT RNAi Designer (Life Technologies, Carlsbad, CA, USA). A 
“universal scramble” shRNA with no homology to any transcripts was used as a control 
(shSCR, sense strand 5′-GCGCTTAGCTGTAGGATTC-3′). An AAV2 shuttle plasmid that 
encodes shCRF or shSCR downstream of the mU6 promoter and enhanced green fluorescent 
protein (EGFP) under the control of the cytomegalovirus (CMV) promoter 3′-flanked by a β-
globin intron was generated using Invitrogen Gateway technology. Helper-free AAV2 
particles were produced by the triple transfection of AAV-293 cells (Agilent Technologies, 
Santa Clara, CA, USA) with the AAV2 shuttle plasmid described above, a plasmid that 
contains AAV2 rep and cap genes, and a plasmid that encodes the adenovirus helper 
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functions. Two days later, cells were collected and lysed by three freeze-thaw cycles, treated 
with benzonase, and clarified by centrifugation. Viral vectors were purified by iodixanol 
gradient ultracentrifugation (Zolotukhin et al., 2002), followed by dialysis and concentration 
against Dulbecco phosphate-buffered saline (PBS) using centrifugal filter units (Millipore, 
Billerica, MA, USA). Genomic units (GU) were quantified by RT-PCR. The titers were 4.5–
6.6 × 1011 GU/ml.
Viral vector and drug infusion
Mice and rats were anesthetized (1–5% isoflurane in oxygen mixture) and placed in a Kopf 
stereotaxic instrument. Double cannulae (Plastics One, Roanoke, VA, USA) were inserted 
bilaterally above the left and right VTA. The coordinates used were relative to bregma and 
from skull surface. Mouse coordinates: aVTA (anterior/posterior [AP], −3.3 mm; dorsal/
ventral [DV], −4.4 mm; medial/lateral [ML], ±0.5 mm), pVTA (AP, −3.6 mm; DV, −4.4 
mm; ML, ±0.5 mm). Each rat received two injections of the virus directed at different AP 
levels of the VTA. Rat coordinates: AP, −5.4 and −5.8 mm; ML, ±0.7 mm; DV, −8.2 mm. 
Each mouse received 0.75 μl/side and each rat received 1 μl/side of either the AAV2-shCRF 
or AAV2-shSCR at an infusion rate of 0.1 μl/min using injectors that protruded 1 mm 
beyond the cannula (for mice) or 2 mm beyond the cannula (for rats). The injectors were left 
in place for 10 additional minutes to ensure adequate diffusion of the solution. Infusions 
were delivered via polyethylene tubing (PE 20) that was connected to a Hamilton 10 μl 
syringe.
For intra-VTA MPZP infusion, dummy cannulae were secured in the injection cannulae by 
dust caps, and the animals were allowed to recover for 1 week prior to drug infusion and 
conditioning. On conditioning days, the dust cap and dummy cannulae were removed and 
replaced with injector cannulae. Mice were lightly restrained and infused with 0.14 μg/0.3 μl 
MPZP or 20% HBC (control solution) over 1 min. After the behavioral experiments were 
completed, the mice were sacrificed and perfused, and cannula placement was verified by 
Cresyl violet staining. Sixteen of 100 mice were excluded due to incorrect cannula 
placements.
Real-time RT-PCR
RNA was isolated using a Qiagen RNeasy extraction kit with DNAase to remove genomic 
DNA contamination, and a specified amount of cDNA was reverse-transcribed using 
Superscript III (Invitrogen, Foster City, CA, USA). Quantitative RT-PCR was performed 
using Taqman Gene Expression Assays for CRF (Crh, Mm01293920_s1) in a 7900HT Fast 
RT-PCR System (both from Life Technologies, Carlsbad, CA, USA). Quantification was 
performed using the ΔCt method with GAPDH as an endogenous control. For single-cell 
RT-PCR analysis, single cells were harvested from AAV2-shCRF- or AAV2-shSCR-
injected brain slices by aspiration of neuronal cytoplasm immediately after 
electrophysiological recordings and processed with the Picopure RNA isolation kit (Life 
Technologies, Carlsbad, CA, USA) for RNA isolation and reverse transcription (RT) using 
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The cDNA obtained from 
single neurons was subjected to preamplification for 20 cycles, followed by RT-PCR to 
detect the expression of TH with forward (5-ACTGCTTCTCAACCACATCTT-3) and 
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reverse (5-GGGTAGAATACAGCATGAAGGG-3) primers using the SSO Advanced 
SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) according to manufacturer’s 
protocol.
Radioactive in situ hybridization
The mice were anesthetized with chloral hydrate (350 mg/kg, i.p.) and perfused via the 
ascending aorta with 0.9% saline followed by ice-cold 4% paraformaldehyde in 0.1 M 
borate buffer, pH 9.5. The brains were removed, postfixed for 3 h, and cryoprotected in 20% 
sucrose in 0.1 M phosphate buffer overnight at 4°C. Five one-in-four series of 30 μm-thick 
frozen coronal sections were cut, collected, and stored in 30% ethylene glycol and 20% 
glycerol in 0.1 M phosphate buffer at −20°C until processing. In situ hybridization was 
performed using 35S-labeled sense (control) and antisense cRNA probes labeled to similar 
specific activities using a full-length (1.2 kb) probe for mRNA that encodes CRF (1.2 kb; 
Dr. K. Mayo, Northwestern University, Evanston, IL, USA). Sections were mounted on 
Superfrost plus slides and dried under vacuum overnight. They were postfixed with 10% 
formalin for 30 min at room temperature, digested with 10 μg/ml proteinase K for 15 min at 
37°C, and acetylated for 10 min. The probes were labeled to specific activities of 1–3 × 109 
dpm/μg and applied to the slides at concentrations of ~107 cpm/ml overnight at 56°C in a 
solution that contained 50% formamide, 0.3 M NaCl, 10 mM Tris, 1 mM EDTA, 0.05% 
tRNA, 10 mM dithiothreitol, 1× Denhardt’s solution, and 10% dextran sulfate, after which 
they were treated with 20 μg/ml of ribonuclease A for 30 min at 37°C and washed in 15 mM 
NaCl/1.5 mM sodium citrate with 50% formamide at 70°C. The slides were then dehydrated 
and exposed to X-ray film (Kodak Biomax MR, Eastman Kodak, Rochester, NY, USA) for 
18 h. They were coated with Kodak NTB-2 liquid emulsion and exposed at 4°C for 3–4 
weeks as determined by the strength of the signal on the film. The slides were developed 
with Kodak D-19 and fixed with Kodak rapid fixer. One series of sections that adjoined 
those used for analysis was stained with thionin to facilitate the accurate localization of 
hybridization signals. The experimenters were blind to the experimental history of the 
animals.
Densitometry
The semiquantitative densitometric analysis of hybridization signals for CRF mRNA was 
performed on emulsion-dipped slides. Photomicrographs were captured using a Leica light 
microscope with a Hamamatsu Orca charge-coupled device camera through OpenLab 
software (version 3.1.5) and analyzed using ImageJ software. The optical densities of 
hybridization signals were determined under dark-field illumination at 400× magnification 
with a circular region of interest (ROI) with a 20 μm diameter that was placed over 
individual neurons. The size of the ROI was chosen on the basis of the average diameter of 
TH-immunoreactive neurons in the pVTA. The sections were analyzed at regular 120 μm 
intervals across the pVTA. Optical densities were corrected for the average background 
signal that was determined by sampling 20 cell-sized areas per section in non-signal areas 
adjacent to the pVTA. Optical density values are expressed in gray scale values of 1 to 256, 
corresponding to a gradation from low to high absorbance, respectively. Neurons on both 
sides of the brain were pooled for analysis to calculate the animal mean. Animal means were 
then grouped according to virus treatment, averaged, and statistically analyzed. The 
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experimenters were blind to the experimental history of the animals during densitometry 
analysis.
Immunohistochemistry
Mice were anesthetized with 3% halothane, pre-perfused transcardially with a solution of 
0.5 ml heparin/100 ml saline for 1–2 min, and then perfused with a solution of 4% 
paraformaldehyde in 0.1M phosphate buffer (PB), pH 7. The experimenters were blind to 
the drug history of the animals. The brains were removed from the skull, post-fixed at 4°C in 
the perfusate solution for 6–18 h, rinsed in several changes of PBS that contained 20% 
sucrose, and stored at 4°C in fresh 20% sucrose/PBS that contained 0.1% sodium azide. 
Coronal cryostat sections (40 μm) were obtained using a Reichert Jung cryostat. The 
sections were collected in strict anatomical order in a one-in-four series and stored at 4°C in 
PBS 0.1% azide prior to processing. The sections were incubated free-floating with shaking 
in multi-well plates, and all incubations were performed at room temperature unless 
otherwise specified. The samples were incubated for 20 min in 1% hydrogen peroxide/PBS 
to quench endogenous peroxidases, rinsed several times in PBS, and exposed to a blocking 
solution that contained PBS/Triton-X100 (0.3%), 1 mg/ml bovine serum albumin (BSA), 
and 5% normal donkey serum (Jackson Immuno Research, West Grove, PA, USA) for a 
minimum of 60 min. The sections were incubated overnight at 4°C in anti-CRF purified goat 
polyclonal antibody (sc-1761, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 
1:200 in PBS, 0.5% Tween 20, and 5% normal donkey serum. Control sections were 
incubated in the antibody diluent. Following three rinses of 10 min each in PBS, the sections 
were incubated in Vector ImmPRESS Goat (Vector Labs, Burlingame, CA, USA) for 1 h, 
rinsed in PBS as above, and reacted with a DAB Substrate Kit (Vector Labs). The sections 
were monitored under a microscope to determine the optimal reaction time. The reaction 
was stopped in PBS. The sections were mounted on coated slides, air dried, dehydrated 
through a series of ethanol and xylene, and coverslipped with Permount. All brightfield 
photographs for analysis were taken with a Q Imaging Retiga 2000R color digital camera 
mounted on a Zeiss Axiophot microscope.
Combined TH immunohistochemistry and CRF fluorescent in situ hybridization
Mouse brains were snap-frozen using isopentane. Twenty-micrometer cryostat sections were 
mounted onto Superfrost Plus slides. A digoxigenin (DIG)-labeled CRF riboprobe was 
synthesized using a commercial kit (Roche, Indianapolis, IN, USA) from a plasmid 
containing full-length rat CRF cDNA (kind donation from Dr. K. Mayo, Northwestern 
University, Evanston, IL, USA). The sections were post-fixed in 4% formaldehyde for 1 
min. Following PBS washes, proteins were acetylated in 0.1 M triethanolamine, pH 8.0, and 
0.2% acetic acid. Following washes in 2× saline sodium citrate buffer, the sections were 
dehydrated in a graded ethanol-chloroform series. Pre-hybridization and hybridization were 
then performed at 70°C in a buffer containing 50% formamide, 2× SSC, 5× Denhardt’s, 0.5 
mg/ml sheared salmon sperm DNA, and 0.25 mg/ml yeast RNA. The probe was diluted in 
the hybridization buffer (800 ng/ml) and incubated overnight on slides. Post-hybridization 
washes were performed in 50% formamide, 2× SSC, and 0.1% Tween-20. The slides were 
then blocked for 1 h and incubated with anti-DIG antibody conjugated to alkaline 
phosphatase (11093274910, 1:1000; Roche) and anti-TH antibody (AB152, 1:500; 
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Millipore, Billerica, MA, USA) overnight at 4°C in TNT buffer (0.1 M Tris, pH 7.5, 0.15 M 
NaCl, 0.1% Tween-20) containing 1% blocking reagent (Roche). A donkey anti-rabbit 
secondary antibody conjugated to Alexa Fluor 488 (A-21206, 1:200, 2 h; Life Technologies, 
Carlsbad, CA, USA) was used to reveal the TH signal. Following TNT washes and 
incubation in 0.1 M Tris-HCl, pH 8, 0.1 M NaCl, 0.01 M MgCl2, HNPP combined with Fast 
Red TR (Roche) was then used to detect alkaline phosphatase. To enhance the signal, fresh 
substrate was applied three times for 30 min, and the slides were rinsed in TNT in-between. 
The slides were washed, air dried, and coverslipped with Vectashield HardSet-DAPI (Vector 
Laboratories, Burlingame, CA, USA). Images were taken using either epifluorescence (Zeiss 
Axiophot) or confocal microscopy (LaserSharp 2000, version 5.2; 488, 568, and 647 nm 
emission wavelengths; Bio-Rad, Hercules, CA, USA).
Human Brain samples (TH immunohistochemistry and CRF chromogenic in situ 
hybridization)
Human brain samples (snap-frozen and stored at −80 degrees) were obtained from the 
UCLA Brain Bank. For chromogenic in situ hybridization, brain sections were processed as 
described above for fluorescent in situ hybridization, but slides were incubated with NBT-
BCIP (Sigma) as an alkaline phosphatase substrate at room temperature overnight in the 
dark. Sections were then rinsed in PBS Tween-20, and air-dried.
For double-labeling with TH, sections were then fixed in 4% paraformaldehyde/PBS for 15 
min, rinsed in PBS, quenched for 20 min in 1% hydrogen peroxide/PBS, rinsed in PBS and 
blocked for 1 h at room temperature in PBS/TX100 (0.3%), BSA (1 mg/ml) and 5% normal 
donkey serum (Jackson). Sections were incubated in rabbit polyclonal TH antibody (Rabbit 
Millipore AB152) and diluted 1:1000 in PBS, 0.5% Tween 20, and 5% normal donkey 
serum overnight at room temperature in a humidity chamber. Following PBS rinses, the 
sections were incubated in Rabbit ImmPRESS (Vector Labs) for 1–2 h at room temperature. 
Following PBS rinses, the sections were incubated in either Vector ImmPACT Red (Vector 
Labs) or DAB substrate (Vector Labs). The reaction was stopped in PBS rinses and the 
sections were air-dried and coverslipped with DPX.
Brain slice preparation (electrophysiology)
Slices that contained the VTA were prepared as described previously24 from 20 adult male 
C57BL/6 mice subjected to brief anesthesia (3–5% isoflurane) followed by rapid 
decapitation and removal of the brain to an ice-cold high-sucrose solution (pH 7.3–7.4) that 
contained 206.0in mM sucrose, 2.5 mM KCl, 0.5 mM CaCl2, 7.0 mM MgCl2, 1.2 mM 
NaH2PO4, 26 mM NaHCO3, 5.0 mM glucose, and 5 mM HEPES. The brains were cut into 
transverse sections (300 μm) on a vibrating microtome (Leica VT1000S, Leica 
Microsystems, Buffalo Grove, IL, USA) and placed in an oxygenated (95% O2/5% CO2) 
artificial cerebrospinal fluid (aCSF) solution composed of the following: 120 mM NaCl, 2.5 
mM KCl, 5 mM EGTA, 2.0 mM CaCl2, 1.0 mM MgCl2, 1.2 mM NaH2PO4, 26 mM 
NaHCO3, 1.75 mM glucose, and 5 mM HEPES. The slices were incubated in this solution 
for 30 min at 35–37°C, followed by 30 min equilibration at room temperature (21–22°C). 
Following equilibration, a single slice was transferred to a recording chamber mounted on 
the stage of an upright microscope (Olympus BX50WI).
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Electrophysiological recording
Neurons were visualized on an upright microscope (Olympus BX50WI) with infrared 
differential interference contrast (IR-DIC) optics and an EXi Aqua camera (QImaging, 
Surrey, BC, Canada). To avoid photolytic damage, initial exposure to episcopic fluorescent 
illumination was brief (< 2 s). Fluorescence was detected using an X-Cite 120Q fluorescent 
illumination system (Lumen Dynamics, Mississauga, Ontario, Canada), and images were 
captured using QCapture software (QImaging). In all cases, the experimenter was blind to 
the nature of the viral vector injected into the mouse prior to experimental recording and 
data analysis. Whole-cell (voltage- and current-clamp) recordings were made with patch 
pipettes (3–5 MΩ; Warner Instruments) coupled to a Multiclamp 700B amplifier (Molecular 
Devices, Sunnyvale, CA, USA), low-pass filtered at 2–5 kHz, digitized (Digidata 1440A; 
Axon Instruments), and stored on a computer using pClamp 10 software (Axon 
Instruments). Series resistance was typically < 10 MΩ and continuously monitored with a 
hyperpolarizing 10 mV pulse. The intracellular solution used for recordings was composed 
of 145in mM KCl, 5 mM EGTA, 5 mM MgCl2, 10 mM HEPES, 2 mM Na-ATP, and 0.2 
mM Na-GTP. To isolate only the inhibitory currents mediated by GABAA receptors, 
recordings (Vhold= −60mV) were performed in the presence of the glutamate receptor 
blockers 6,7-dinitroquinoxaline-2,3-dione (DNQX; 20 μM) and DL-2-amino-5-
phosphonovalerate (AP-5; 50 μM) and the GABAB receptor antagonist CGP55845A (1 μM). 
Due to rapidly desensitizing effects, nicotine was bath applied for 5–7 min, but the period of 
analysis was restricted to 2 min after full wash-in. The frequency, amplitude, and decay of 
spontaneous inhibitory postsynaptic currents (sIPSCs) were analyzed and visually confirmed 
using semi-automated, threshold-based, mini-detection software (Mini Analysis, 
Synaptosoft Inc.). We determined averages of IPSC characteristics from baseline and 
experimental drug conditions containing a minimum of 60 events (time period of analysis 
varied as a product of individual event frequency), and we determined decay kinetics using 
exponential curve fittings, which are reported as decay time (ms). All of the detected events 
were used for event frequency analysis, but superimposed events were eliminated for 
amplitude and decay kinetic analysis. Action potential characteristics were evaluated using 
threshold-based event detection analysis in Clampfit 10.2 (Molecular Devices).
Place conditioning
The place conditioning apparatus was obtained from Med Associates (SOF-700RA-25 Two 
Chamber Place Preference Apparatus; St. Albans, VT, USA). One environment was black 
with a metal rod floor, and the other was white with a wire mesh floor. An intermediate gray 
area housed a removable partition. Each cage was cleaned between animals, and each group 
was fully counterbalanced. During preference testing, the dividing partition was removed, 
and the mice were given free access to both environments. A single 10 min preference test 
session was performed 5 days after the last conditioning day. All place conditioning and 
testing were performed between 10:00 AM and 6:00 PM.
The nicotine-dependent and -withdrawn groups of mice were conditioned according to 
modified place conditioning procedures as described previously14. Conditioning occurred 
only during withdrawal from chronic nicotine so that the motivational effects of withdrawal 
but not the direct effects of chronic nicotine were paired with the place conditioning 
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environment. Eight hours after minipump removal, when the mouse was experiencing 
motivational withdrawal from chronic nicotine14, it was subcutaneously or intracranially 
pretreated with vehicle (HBC) or MPZP and confined to one of the conditioning 
environments for 1 h. The difference score for each animal was calculated by subtracting the 
time spent in the non-paired environment from the time spent in the withdrawal-paired 
environment during preference testing.
For nicotine-dependent mice (not withdrawn), conditioning occurred only during exposure 
to chronic nicotine so that the motivational effects of chronic nicotine in a dependent animal 
were paired with the place conditioning environment. The mice were subcutaneously 
pretreated with vehicle (20% HBC) or MPZP (20 mg/kg) and confined to one of the 
conditioning environments for 1 h. The difference score for each animal was calculated by 
subtracting the time spent in the non-paired environment from the time spent in the nicotine-
paired environment during preference testing.
For the acute nicotine experiments, previously drug-naive mice were subcutaneously or 
intracranially pretreated with 20% HBC or MPZP, given a subcutaneous injection of 1.75 
mg/kg nicotine or saline, and immediately confined to one of the conditioning environments 
for 1 h. The next day, the mouse was pretreated again with HBC or MPZP, given acute 
saline or nicotine, and confined to the other environment. The difference score for each 
animal was calculated by subtracting the time spent in the saline-paired environment from 
the time spent in the nicotine-paired environment. In all cases, the experimenter was blind to 
the previous drug and/or viral vector treatment.
Open field testing
Mice were placed in the center of a gray box measuring 41 × 41 × 38 cm for 5 min. The 
room was dark with the open field testing box illuminated by a soft red light. Locomotor 
activity and time spent in the center square area of the box were recorded by a video camera 
and calculated by the monitoring program (Ethovision XT, Noldus; Leesburg, VA, USA). 
The experimenter was blind to the mouse’s previous drug and viral vector history. The test 
box was cleaned with 70% alcohol between each mouse.
Nicotine self-administration
Two weeks following infusion, rats were implanted with intravenous catheters in the jugular 
vein under isoflurane anesthesia as described previously29. Detailed procedures for the 
escalation of nicotine self-administration have been described previously29. Briefly, three 
weeks following the injection of viral vectors in the VTA, rats were trained to nosepoke for 
food and water within their self-administration chambers in 21-h sessions but were not food-
trained to respond for the lever that was associated with nicotine delivery. Subsequently, the 
active and inactive levers were extended, and the rats were allowed to self-administer 
nicotine (0.03251658240 or 0.0 mg/kg per 100251658240 μl/1251658240 s, free base, FR1, 
timeout 20 s) for 10 days (1 h per day). The rats were then allowed daily long access (LgA; 
21 h) nicotine/saline self-administration sessions for 7 consecutive days, followed by 48 h of 
abstinence and another LgA session to measure abstinence-induced escalation of nicotine 
intake.
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Statistical analysis
The behavioral data were analyzed with Statistica software using a one- or two-way 
ANOVA or Student’s t-test, where appropriate. In all cases, a normality test and an equal 
variance test were performed before the ANOVA to ensure its validity. For 
electrophysiology, statistical analysis was performed using Prism 5.02 software (GraphPad, 
San Diego, CA). Groups were analyzed for independent significance using a one-sample t-
test, compared using an unpaired t-test for comparisons between two groups, and a one-way 
ANOVA for comparisons between three or more groups. All of the experiments and 
analyses were performed by experimenters who were blind to the treatments, and the 
animals’ order of treatment was randomized. No statistical methods were used to 
predetermine sample sizes, but our sample sizes are similar to those reported in previous 
publications13,25,37,39. Different numbers of animals between groups and between the 
beginning and end of the study are a result of the loss of data due to improper cannula 
placement, improper brain perfusion, damaged brain samples, or computer failure during 
testing. For all of the analyses, Bonferroni post hoc tests were used when appropriate. All of 
the data are expressed as mean ± standard “A supplementary methods checklist is 
available”.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Nicotine dependence increases CRF mRNA levels in the VTA
a, Location of the brain tissue samples in the CeA, VTA, and PVN. b, CRF mRNA levels 
(ΔCt) in the CeA, VTA, and PVN relative to the housekeeping gene GAPDH normalized to 
saline in mice chronically exposed to saline (Sal) or nicotine (Nic) or withdrawn from 
chronic nicotine (WD) as measured by RT-PCR (n = 13–14 per group). A significant change 
in CRF mRNA was observed in the VTA but not CeA or PVN in both the Nic and WD 
groups (*p < 0.05, vs. Sal). Data represent mean ± SEM.
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Fig. 2. Identification of VTA CRF neurons in mice
a, Number of CRF neurons per section in the VTA (bregma range: −2.92 to −3.88) in mice 
(n = 24). Data represent mean ± SEM. b, Representative CRF mRNA in situ hybridization 
sections of the anterior (aVTA), posterior (pVTA), and tail (tVTA) of the VTA in naive 
mice. White arrows point to CRF neurons. c, Corresponding diagram from the Paxinos and 
Watson atlas. Scale bar = 200 μm
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Fig. 3. Double labeling of CRF/DA neurons using CRF in situ hybridization and TH 
immunohistochemistry in mice
a, CRF mRNA radioactive in situ hybridization (black) demonstrating CRF-positive cell 
bodies (arrows) in the pVTA. b, TH immunohistochemistry (red) on an alternate section of 
the pVTA showing that dopaminergic cell bodies were located bilaterally in the pVTA in 
TH-immunoreactive areas. c, Double fluorescent labeling of CRF mRNA (red) and TH 
protein (green) in the pVTA at high magnification. Fluorescent ISH is less sensitive than 
radioactive or chromogenic ISH; thus, a limited number of neurons expressing CRF mRNA 
could be identified in the pVTA in nicotine-dependent mice using this procedure. However, 
it was used to achieve high-resolution imaging and assess the cellular colocalization of CRF 
mRNA with TH. Of 18 neurons that unambiguously expressed CRF mRNA, 16 were TH-
positive (CRF+/TH+ neuron: arrow, CRF−/TH+ neuron: arrowhead). d, Confocal image of a 
single VTA neuron co-expressing TH and CRF mRNA. This experiment was repeated on 13 
sections from three mice.
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Fig. 4. Double labeling of CRF/DA neurons using CRF in situ hybridization and TH 
immunohistochemistry in humans
Single TH immunohistochemistry (a, d, g, light brown) and CRF ISH (b, e, h, blue) 
performed on different but adjacent sections (distance: 80 μm) of the VTA (human sample 
HSB3750). Notice the similar distribution of TH (white arrow head) and CRF (black 
arrowhead) within the VTA (use blood vessel * as landmark). Double TH immunochemistry 
and CRF ISH (c, f, i) on the same section (adjacent to the other two sections; note blood 
vessel *). White arrows point to colocalized TH/CRF neurons. Very few neurons were 
single-labeled as TH-only (white arrow head) and CRF-only (black arrowhead). This 
experiment was repeated on brain samples from three human subjects.
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Fig. 5. Nicotine dependence causes dysregulation of GABA-DA synapses, which is reversed by 
downregulation of CRF mRNA
a, Representative voltage-clamp recording of sIPSCs in a pVTA DA neuron from a naive 
mouse before and during the application of nicotine (1 μM). b, Box-and-whisker plot of 
average sIPSC frequency before and during nicotine application (n = 8 cells from three 
mice). c, 60× magnification photomicrograph of a pVTA DA neuron from a nicotine-
dependent mouse using fluorescent optics to illustrate GFP expression (left panel) and 
infrared differential interference contrast (IR-DIC) optics during recording (right panel, * 
pipette). d, Representative voltage-clamp recording of sIPSCs in a pVTA DA neuron from a 
nicotine-dependent mouse injected with AAV2-shSCR before and during application of 
nicotine (1 μM). e, Representative voltage-clamp recording of sIPSCs in a pVTA DA neuron 
from a nicotine-dependent mouse injected with AAV2-shCRF before and during application 
of nicotine (1 μM). f, Summary of average change in sIPSC frequency produced by nicotine 
(*p < 0.05) in pVTA DA neurons from naive mice (n = 8 cells from three mice), naive mice 
injected with either AAV2-shSCR (n = 12 cells from three mice), or AAV2-shCRF (n = 12 
cells from three mice) and nicotine-dependent mice injected with either AAV2-shSCR (n = 
Grieder et al. Page 25
Nat Neurosci. Author manuscript; available in PMC 2015 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
11 cells from four mice) or AAV2-shCRF (n = 10 cells from four mice; #p = 0.0003, vs. 
nicotine-dependent AAV2-shSCR). Data represent mean ± SEM.
Grieder et al. Page 26
Nat Neurosci. Author manuscript; available in PMC 2015 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 6. Viral vector-mediated downregulation of CRF mRNA in the VTA prevents the aversive 
motivational response to nicotine withdrawal
a, Timeline of experiment. b, Difference score (s) during testing of conditioned place 
aversion to nicotine withdrawal in nicotine-dependent and -withdrawn groups or 
nondependent groups given acute nicotine after AAV2-shSCR or AAV2-shCRF treatment 
(n = 11 mice per group). Mice infused with the silencing vector did not show the 
conditioned aversive motivational response (a negative difference score) to withdrawal from 
chronic nicotine (*p < 0.05) that was observed in mice given the control vector. 
Nondependent mice given AAV2-shSCR or AAV2-shCRF showed an aversive response to 
acute nicotine. Data represent mean ± SEM. The inset shows the viral vector injection site. 
c, Box-and-whisker plot showing time spent in the central area of the open field in nicotine-
dependent and -withdrawn mice injected with AAV2-shSCR (n = 8) or AAV2-shCRF in the 
VTA (n = 8; *p < 0.05). Pictures below are example traces showing activity patterns in the 
open field of a mouse injected with the corresponding vector. See Fig. S5 for details on the 
viral vector.
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Fig. 7. Viral vector-mediated downregulation of CRF mRNA in the VTA decreases long-access 
nicotine self-administration and prevents abstinence-induced escalation of nicotine intake
a, Number of nicotine self-administrations in rats injected with AAV2-shSCR or AAV2-
shCRF and given short access (1 h/day for 10 days; ShA-AAV2-shCRF, n = 9; ShA-AAV2-
shSCR, n = 9), long access (21 h/day for 7 days; LgA-AAV2-shCRF, n = 8; LgA-AAV2-
shSCR, n = 7), or long access after 48 h of abstinence (LgA + abstinence; n = 11) to 
nicotine. AAV2-shCRF reduced the amount of nicotine infusions in the LgA group (*p < 
0.05, vs. AAV2-shSCR) and LgA + abstinence group (**p < 0.001, vs. AAV2-shSCR). 
Comparisons of the AAV2-shSCR LgA groups before and after abstinence with regard to 
the number of infusions after abstinence demonstrate the abstinence-induced escalation of 
nicotine intake (#p < 0.05). Data represent mean ± SEM. b. Representative section of 
AAV2-shCRF using GFP ISH (dark blue). c, Viral vector injection site.
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Fig. 8. CRF1 receptor antagonism prevents the aversive motivational response to withdrawal 
from chronic nicotine
a, Timeline of experiment. b, Nicotine-dependent and -withdrawn mice pretreated with 
vehicle (n = 13) showed an aversion to the withdrawal-paired environment that was blocked 
by pretreatment with the CRF1 receptor antagonist MPZP (n = 14; *p < 0.05). Nicotine-
dependent mice that were not experiencing withdrawal and were pretreated with vehicle (n = 
15) showed a preference for the nicotine-paired environment that was not blocked by MPZP 
pretreatment (n = 15). Nondependent mice given acute nicotine and pretreated with vehicle 
(n = 16) showed an aversion to the nicotine-paired environment that was not blocked by 
MPZP pretreatment (n = 15). Mice with saline minipumps that were pretreated with vehicle 
(n = 11) or MPZP (n = 12) showed no motivational response to a novel environment or to 
MPZP. Data represent mean ± SEM. c, Schematic of the aVTA showing placements of the 
intra-aVTA cannulae. d. Schematic of the pVTA showing placements of the intra-pVTA 
cannulae. e, Nicotine-dependent and -withdrawn mice implanted with cannulae in the pVTA 
that were given vehicle (n = 11) showed an aversive motivational response to the 
withdrawal-paired environment that was blocked in mice that received intra-pVTA 
CRF1 receptor antagonist MPZP (n = 10; *p < 0.05). Dependent and withdrawn mice 
implanted with aVTA cannulae that were given vehicle (n = 10) or MPZP (n = 12) showed 
nicotine withdrawal aversions. Nondependent mice with pVTA cannulae that were 
pretreated with vehicle (n = 8) or MPZP (n = 10) and acute nicotine showed an aversive 
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motivational response to the nicotine-paired environment. Control mice implanted with 
saline minipumps and pVTA cannulae that received vehicle (n = 12) or MPZP (n = 11) 
showed no motivational response to a novel environment or to MPZP. Data represent mean 
± SEM.
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